S. Ehrenforth

2.6k citations

55 papers · 2.2k · 1 hit paper · h-index 22

Impact in

Hematology top 0.5%
- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Hemostasis and retained surgical items
Internal Medicine top 1%
- Venous Thromboembolism Diagnosis and Management

Papers in

Hematology 45
- Blood Coagulation and Thrombosis Mechanisms 27
- Hemophilia Treatment and Research 26
- Platelet Disorders and Treatments 10
- Chronic Myeloid Leukemia Treatments 7
- Hemostasis and retained surgical items 4
Internal Medicine 10
- Venous Thromboembolism Diagnosis and Management 10

Co-authors: I. Scharrer (25 shared papers)W. Kreuz (16 shared papers)Ulrike Nowak‐Göttl (10 shared papers)B. Kornhuber (8 shared papers)Markus Benedikt Funk (9 shared papers)Tayfun Güngör (4 shared papers)B. Krackhardt (1 shared paper)RICHARD W. TE LINDE (4 shared papers)
Journals: Thrombosis and Haemostasis (8 papers)Blood (6 papers)European Journal of Pediatrics (6 papers)Journal of Thrombosis and Haemostasis (4 papers)The Lancet (3 papers)
Partner nations: Germany Denmark United States

In The Last Decade

S. Ehrenforth

51 papers receiving 2.1k citations

S. Ehrenforth's Hit Papers

align trajectories log scale

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs 1992 · 510 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

1992 The Lancet

Peers

Countries citing papers authored by S. Ehrenforth

Since Specialization

Citations

This map shows the geographic impact of S. Ehrenforth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Ehrenforth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Ehrenforth more than expected).

Fields of papers citing papers by S. Ehrenforth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Ehrenforth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Ehrenforth. The network helps show where S. Ehrenforth may publish in the future.

Co-authors

The 25 scholars most cited alongside S. Ehrenforth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Ehrenforth Line = papers co-authored together S. Ehrenforth links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs The Lancet ·S. Ehrenforth, W. Kreuz, RICHARD W. TE LINDE, Markus Benedikt Funk, Tayfun Güngör, B. Krackhardt, B. Kornhuber, I. Scharrer Hit paper breakdown →	1992	510
2	Prospective Evaluation of the Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors Blood ·Ulrike Nowak‐Göttl, Cornelia Wermes, Ralf Junker, Hans-Georg Koch, Rosmarie Schobess, Gudrun Fleischhack, Dirk Schwabe, S. Ehrenforth	1999	168
3	Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism Blood ·Mario von Depka, Ulrike Nowak‐Göttl, Roswith M. Eisert, Christian Dieterich, M. Barthels, I. Scharrer, Arnold Ganser, S. Ehrenforth	2000	160
4	Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood European Journal of Pediatrics ·S. Ehrenforth, R. Junker, Hans Georg Koch, W. Kreuz, Nicole Münchow, I. Scharrer, Ulrike Nowak‐Göttl +1 other	1999	108
5	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A Thrombosis and Haemostasis ·Paul L. F. Giangrande, T. A. Andreeva, Pratima Chowdary, S. Ehrenforth, Hideji Hanabusa, Frank Leebeek, Steven R. Lentz, László Nemes	2016	102
6	Prothrombin G20210A Gene Mutation and Further Prothrombotic Risk Factors in Childhood Thrombophilia Arteriosclerosis Thrombosis and Vascular Biology ·Ralf Junker, Hans-Georg Koch, Karin Auberger, Nicole Münchow, S. Ehrenforth, Ulrike Nowak‐Göttl	1999	99
7	Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia European Journal of Pediatrics ·Heinrich Vielhaber, S. Ehrenforth, Hans Georg Koch, I. Scharrer, Niels R. van der Werf, Ulrike Nowak‐Göttl	1998	93
8	Inhibitor Development in Previously Untreated Patients with Hemophilia A: A Prospective Long-Term Follow-Up Comparing Plasma-Derived and Recombinant Products Seminars in Thrombosis and Hemostasis ·W. Kreuz, Carmen Escuriola Ettingshausen, A. Zyschka, Johannes Oldenburg, Inmaculada Martinez Saguer, S. Ehrenforth, Thomas Klingebiel	2002	70
9	New Insights into the Coagulation System and Implications for New Therapeutic Options with Recombinant Factor VIIa Current Medicinal Chemistry ·Alex Veldman, Maureane Hoffman, S. Ehrenforth	2003	65
10	Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow‐up Haemophilia ·W. Kreuz, S. Ehrenforth, Markus Benedikt Funk, Gunther Auerswald, Dirk Mentzer, Jörg Joseph‐Steiner, Thomas Beeg, Dr Klarman	1995	60
11	Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa Journal of Thrombosis and Haemostasis ·Steven R. Lentz, S. Ehrenforth, Faraizah Abdul Karim, Tadashi Matsushita, Karin Nana Weldingh, Jerzy Windyga, Johnny Ndoni Mahlangu	2014	59
12	Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden The Hematology Journal ·Ingrid Pabinger, László Nemes, C. Rintelen, Silvia Koder, Eckhard Lechler, Ralph M. Loreth, Paul Alexander Kyrle, I. Scharrer	2000	56
13	Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A Thrombosis and Haemostasis ·Sandrine Meunier, Jayanthi Alamelu, S. Ehrenforth, Hideji Hanabusa, Faraizah Abdul Karim, Kaan Kavaklı, Melanie Khodaie, Janice M.R. Staber	2017	51
14	Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity Journal of Thrombosis and Haemostasis ·Johnny Ndoni Mahlangu, Karin Nana Weldingh, Steven R. Lentz, Shipra M. Kaicker, Faraizah Abdul Karim, Tadashi Matsushita, Michael Recht, Waldemar Tomczak	2015	50
15	The Prothrombin 20210 A Allele Is Frequently Coinherited in Young Carriers of the Factor V Arg 506 to Gln Mutation With Venous Thrombophilia Blood ·S. Ehrenforth, G. Ludwig, Sebastián Klinke, Maren Krause, I. Scharrer, Ulrike Nowak‐Göttl	1998	49
16	Acquired Activated Protein C-Resistance in Patients with Lupus Anticoagulants Thrombosis and Haemostasis ·S. Ehrenforth, Klaus-Peter Radtke, I. Scharrer	1995	47
17	Study of the Prothrombin Gene 20201 GA Variant in FV:Q 506 Carriers in Relationship to the Presence or Absence of Juvenile Venous Thromboembolism Arteriosclerosis Thrombosis and Vascular Biology ·S. Ehrenforth, M. von Depka Prondsinski, Emel Aygören‐Pürsün, U. Nowak-Göttl, I. Scharrer, Arnold Ganser	1999	44
18	Factor VIII inhibitors in haemophiliacs The Lancet ·S. Ehrenforth, W. Kreuz, I. Scharrer, B. Kornhuber	1992	41
19	Liver Damage Induced by Coumarin Anticoagulants Seminars in Thrombosis and Hemostasis ·S. Ehrenforth, Joachim F. Schenk, I. Scharrer	1999	40
20	Factor VIII Inhibitors in Patients with Hemophilia A: Epidemiology of Inhibitor Development and Induction of Immune Tolerance for Factor VIII Seminars in Thrombosis and Hemostasis ·W. Kreuz, Sabine Becker, Elisabeth Lenz, Inmaculada Martinez‐Saguer, Carmen Escuriola Ettingshausen, Markus Benedikt Funk, S. Ehrenforth, Gunther Auerswald	1995	37

About S. Ehrenforth

S. Ehrenforth is a scholar working on Hematology, Internal Medicine, Genetics, Rheumatology and Hepatology, having authored 55 papers that have together received 2.2k indexed citations. Recurring topics across this work include Blood Coagulation and Thrombosis Mechanisms (27 papers), Hemophilia Treatment and Research (26 papers), Platelet Disorders and Treatments (10 papers), Venous Thromboembolism Diagnosis and Management (10 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (8 papers), Chronic Myeloid Leukemia Treatments (7 papers), Hemostasis and retained surgical items (4 papers) and Lipoproteins and Cardiovascular Health (2 papers). The work is most often cited by research in Hematology (1.7k citations), Internal Medicine (396 citations), Genetics (343 citations), Cardiology and Cardiovascular Medicine (237 citations) and Obstetrics and Gynecology (65 citations). S. Ehrenforth has collaborated with scholars based in Germany, Denmark and United States. Frequent co-authors include I. Scharrer, W. Kreuz, Ulrike Nowak‐Göttl, B. Kornhuber, Markus Benedikt Funk, Tayfun Güngör, B. Krackhardt, RICHARD W. TE LINDE, Hans-Georg Koch and Ralf Junker. Their work appears in journals such as Thrombosis and Haemostasis, Blood, European Journal of Pediatrics, Journal of Thrombosis and Haemostasis and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

S. Ehrenforth

Impact in

Papers in i

In The Last Decade

S. Ehrenforth

S. Ehrenforth's Hit Papers

Peers

Countries citing papers authored by S. Ehrenforth

Fields of papers citing papers by S. Ehrenforth

All Works

About S. Ehrenforth

Explore authors with similar magnitude of impact

Papers in